key: cord-0719974-7mel36tv
authors: Mogami, Tae; Onuma, Emi; Aoki, Mihoko; Kamiya, Natsuko; Sukegawa, Akiko; Miyagi, Etsuko; Sakakibara, Hideya
title: Increased anxiety and depression in patients with gynecologic cancers during the COVID‐19 pandemic: A retrospective study from Japan
date: 2020-12-29
journal: Int J Gynaecol Obstet
DOI: 10.1002/ijgo.13470
sha: 6c4d5f604485c732890adfe12497591f2dfe961f
doc_id: 719974
cord_uid: 7mel36tv

Patients with cancer frequently have problems related to anxiety or depression [1]. With the insurgence of the coronavirus disease 2019 (COVID-19) pandemic, fear and uncertainty have increased in the general population. Moreover, with the widespread media information that cancer can be a risk factor for severe COVID-19, anxiety tends to increase in patients with cancer. Additionally, the decrease in face-to-face communication with their peers can predispose them to depression.

depression. 1 With the insurgence of the coronavirus disease 2019 (COVID-19) pandemic, fear and uncertainty have increased in the general population. Moreover, with the widespread media information that cancer can be a risk factor for severe COVID-19, anxiety tends to increase in patients with cancer. Additionally, the decrease in face-to-face communication with their peers can predispose them to depression.

We conducted a Yokohama City University IRB-approved retrospective study, wherein we included patients from our hospital with gynecologic cancers who had been screened for anxiety and depression during the Japanese government-ordered state of emergency against COVID-19. We used self-adminis- (Table 1) . A significantly greater proportion of patients with ovarian and peritoneal cancer, as well as advanced-stage cancers, were undergoing treatment compared to the post-treatment group. The DIT and HADS anxiety scores were higher in patients undergoing treatment than in the follow-up group. One third of the patients undergoing cancer treatment showed a significantly high anxiety score. Surprisingly, 50% of patients showed a high depression score in both groups, which was higher than the proportion in a previous study. 1 Patients who were tested at least Our study has some limitations. Due to the possible selection bias, the results cannot be generalized. Moreover, the sample size was small; therefore, we could not rule out possible confounding factors such as origin and stage of cancer.

In Japan, the first wave of the pandemic was not as enormous as that in other developed countries. Nevertheless, this study revealed anxiety and depression in a high proportion of patients with cancer.

This might be due to the number of planned visits of patients with cancer, which did not considerably decrease in our hospital.

In summary, during the first wave of the COVID-19 pandemic in Japan, 50% of patients with cancer were depressed, and many patients who were undergoing cancer treatment were distressed and anxious. Further careful psychological evaluation of patients with cancer will be required during the next wave of the pandemic.

The authors thank Dr Shin Saito and Dr Yukiko Okada for their substantial support.

The authors have no conflicts of interest.

TM, EO, NK, AS, EM, and HS conceived and designed the study and wrote the manuscript. TM, EO, and MA collected data. TM planned and conducted the study and performed data analysis.

Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type

Development of an impact thermometer for use in combination with the distress thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients

The hospital anxiety and depression scale

Screening for psychological distress in Japanese cancer patients